Weil Company Inc. Has $367,000 Stock Position in AbbVie Inc. $ABBV

Weil Company Inc. lowered its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 11.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,980 shares of the company’s stock after selling 252 shares during the quarter. Weil Company Inc.’s holdings in AbbVie were worth $367,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of ABBV. Nwam LLC raised its position in shares of AbbVie by 2.3% in the second quarter. Nwam LLC now owns 20,850 shares of the company’s stock valued at $3,916,000 after purchasing an additional 472 shares during the period. Keynote Financial Services LLC raised its holdings in AbbVie by 0.4% in the 2nd quarter. Keynote Financial Services LLC now owns 40,880 shares of the company’s stock worth $7,588,000 after acquiring an additional 144 shares during the period. Blackston Financial Advisory Group LLC lifted its position in AbbVie by 5.6% during the 2nd quarter. Blackston Financial Advisory Group LLC now owns 5,193 shares of the company’s stock worth $964,000 after acquiring an additional 274 shares during the last quarter. 49 Wealth Management LLC boosted its holdings in AbbVie by 7.5% during the second quarter. 49 Wealth Management LLC now owns 7,107 shares of the company’s stock valued at $1,319,000 after acquiring an additional 497 shares during the period. Finally, Ibex Wealth Advisors grew its position in shares of AbbVie by 2.8% in the second quarter. Ibex Wealth Advisors now owns 58,426 shares of the company’s stock valued at $10,845,000 after purchasing an additional 1,610 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Trading Down 0.4%

Shares of ABBV opened at $218.31 on Tuesday. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The stock has a market cap of $385.84 billion, a PE ratio of 103.96, a PEG ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $244.81. The stock has a 50 day simple moving average of $223.40 and a 200-day simple moving average of $202.94.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the prior year, the business posted $3.00 earnings per share. The business’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is currently 524.24%.

Wall Street Analysts Forecast Growth

ABBV has been the subject of several recent analyst reports. Wall Street Zen upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Evercore ISI upped their price objective on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research report on Monday, September 22nd. Daiwa Capital Markets upgraded shares of AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 target price for the company in a research note on Thursday, August 7th. JPMorgan Chase & Co. boosted their price target on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Finally, HSBC set a $225.00 price target on AbbVie in a report on Thursday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $236.57.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.